Two Sigma Advisers
TVTX icon

Two Sigma Advisers’s Travere Therapeutics TVTX Stock Holding History

Two Sigma Advisers’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-725,500
Closed -$27.7M – 2009
2025
Q4 		$27.7M Buy
725,500
+28,800
+4% +$936K 0.05% 271
2025
Q3 		$16.7M Sell
696,700
-361,000
-34% -$6.79M 0.03% 369
2025
Q2 		$15.7M Buy
1,057,700
+12,000
+1% +$199K 0.03% 388
2025
Q1 		$18.7M Buy
1,045,700
+78,200
+8% +$1.59M 0.04% 343
2024
Q4 		$16.9M Buy
967,500
+247,100
+34% +$4.37M 0.04% 364
2024
Q3 		$10.1M Buy
720,400
+167,100
+30% +$1.74M 0.02% 487
2024
Q2 		$4.55M Sell
553,300
-146,900
-21% -$989K 0.01% 800
2024
Q1 		$5.4M Buy
700,200
+157,400
+29% +$1.33M 0.01% 746
2023
Q4 		$4.88M Sell
542,800
-34,100
-6% -$248K 0.01% 810
2023
Q3 		$5.16M Sell
576,900
-107,900
-16% -$1.52M 0.01% 717
2023
Q2 		$10.5M Sell
684,800
-36,800
-5% -$669K 0.03% 466
2023
Q1 		$16.2M Buy
721,600
+420,500
+140% +$8.94M 0.04% 393
2022
Q4 		$6.33M Buy
301,100
+92,000
+44% +$1.95M 0.02% 682
2022
Q3 		$5.15M Buy
209,100
+35,800
+21% +$925K 0.01% 718
2022
Q2 		$4.2M Buy
173,300
+78,600
+83% +$1.98M 0.01% 854
2022
Q1 		$2.44M Buy
94,700
+47,000
+99% +$1.25M 0.01% 1141
2021
Q4 		$1.48M Buy
+47,700
New +$1.34M ﹤0.01% 1343
2021
Q2 		– Sell
-125,900
Closed -$3.14M – 2701
2021
Q1 		$3.14M Sell
125,900
-31,700
-20% -$876K 0.01% 1054
2020
Q4 		$4.29M Sell
157,600
-23,400
-13% -$546K 0.01% 888
2020
Q3 		$3.34M Sell
181,000
-71,500
-28% -$1.39M 0.01% 915
2020
Q2 		$5.15M Sell
252,500
-14,600
-5% -$232K 0.02% 780
2020
Q1 		$3.9M Sell
267,100
-141,418
-35% -$2.13M 0.01% 810
2019
Q4 		$5.8M Buy
408,518
+7,818
+2% +$99.9K 0.01% 790
2019
Q3 		$4.64M Buy
400,700
+166,600
+71% +$2.75M 0.01% 790
2019
Q2 		$4.7M Buy
234,100
+27,200
+13% +$537K 0.01% 851
2019
Q1 		$4.68M Buy
206,900
+109,300
+112% +$2.42M 0.01% 856
2018
Q4 		$2.21M Buy
97,600
+42,100
+76% +$1.05M 0.01% 1132
2018
Q3 		$1.59M Sell
55,500
-22,900
-29% -$655K ﹤0.01% 1332
2018
Q2 		$2.14M Buy
78,400
+39,100
+99% +$1.04M 0.01% 1262
2018
Q1 		$879K Buy
39,300
+2,600
+7% +$61.9K ﹤0.01% 1601
2017
Q4 		$773K Sell
36,700
-34,300
-48% -$784K ﹤0.01% 1614
2017
Q3 		$1.77M Buy
+71,000
New +$1.56M 0.01% 1277
2017
Q2 		– Sell
-44,700
Closed -$825K – 2402
2017
Q1 		$825K Sell
44,700
-8,400
-16% -$164K ﹤0.01% 1676
2016
Q4 		$1M Sell
53,100
-33,800
-39% -$691K ﹤0.01% 1557
2016
Q3 		$1.95M Buy
86,900
+39,100
+82% +$744K 0.01% 1040
2016
Q2 		$851K Sell
47,800
-3,900
-8% -$63.1K ﹤0.01% 1245
2016
Q1 		$706K Sell
51,700
-63,015
-55% -$956K ﹤0.01% 1307
2015
Q4 		$2.21M Sell
114,715
-81,892
-42% -$1.64M 0.01% 717
2015
Q3 		$4.15M Buy
196,607
+189,607
+2,709% +$5.62M 0.03% 524
2015
Q2 		$232K Buy
+7,000
New +$192K ﹤0.01% 1703

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers's TVTX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 725,500 shares — an estimated $27.7M sold.

Two Sigma Advisers first reported a position in TVTX in Q2 2015 and held it in 40 quarters. The position peaked at $27.7M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Two Sigma Advisers reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 725,500 Travere Therapeutics shares in Q1 2026, an estimated $27.7M.
  • Two Sigma Advisers first reported a position in Travere Therapeutics in Q2 2015 and held it in 40 quarters.
  • Two Sigma Advisers's Travere Therapeutics position peaked at $27.7M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.